The page could not be loaded. The CMS.gov Web site currently does not fully support browsers with
There is major trial design flaw in trials.FDA/CMS need to investigate further before anyreimbursement. Placebo patients receivedsignificantly less tcells than Provenge armpatients (pbo only received 1/3 cells back). Thisdifference could have led to effect, but becauseof harm in pbo arm.
Full analysis here:http://mfi.re/?zdiewnyttqg4vnz
Apologies for anon. Very sorry for patients andappreciate there is very vocal support, which hasbecome very threatening to some researcherstherefore staying anon. Even if this is redacted,do examine the trial design analysis to see themassive flaw.